The cannabinoid-1 receptor inverse agonist taranabant reduces abdominal pain and increases intestinal transit in mice

Alternative Targets Within the Endocannabinoid System for Future Treatment of Gastrointestinal Diseases

(2016) Rudolf Schicho et al.   CANADIAN JOURNAL OF GASTROENTEROLOGY

Relapse prevention in UK Stop Smoking Services: current practice, systematic reviews of effectiveness and cost-effectiveness analysis.

(2014) T Coleman et al.   HEALTH TECHNOLOGY ASSESSMENT

Linaclotide, Novel Therapy for the Treatment of Chronic Idiopathic Constipation and Constipation-Predominant Irritable Bowel Syndrome

(2013) Maria I. Vazquez-Roque et al.   ADVANCES IN THERAPY

Inhibition of p38/Mk2 signaling pathway improves the anti-inflammatory effect of WIN55 on mouse experimental colitis

(2013) Yu Y Li et al.   LABORATORY INVESTIGATION

Cannabinoid Receptor 1 in the Vagus Nerve Is Dispensable for Body Weight Homeostasis But Required for Normal Gastrointestinal Motility

(2012) C. R. Vianna et al.   JOURNAL OF NEUROSCIENCE

The Gastrointestinal Pharmacology of Cannabinoids: Focus on Motility

(2012) Raquel Abalo et al.   PHARMACOLOGY

Medical Management of Constipation

(2012) Meredith Portalatin et al.   Clinics in Colon and Rectal Surgery

Current and future therapies for chronic constipation

(2011) J. Tack   BEST PRACTICE & RESEARCH IN CLINICAL GASTROENTEROLOGY

Lubiprostone for the Treatment of Adults with Constipation and Irritable Bowel Syndrome

(2011) Ron Schey et al.   DIGESTIVE DISEASES AND SCIENCES

Efficacy and safety of oral lubiprostone in constipated patients with or without irritable bowel syndrome: a randomized, placebo-controlled and dose-finding study

(2011) S. Fukudo et al.   NEUROGASTROENTEROLOGY AND MOTILITY

Linaclotide, a synthetic guanylate cyclase C agonist, for the treatment of functional gastrointestinal disorders associated with constipation

(2011) Maria Vazquez Roque et al.   Expert Review of Gastroenterology & Hepatology

Neuropsychiatric Adverse Effects of Centrally Acting Antiobesity Drugs

(2010) Pradeep J. Nathan et al.   CNS Neuroscience & Therapeutics

A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose study

(2010) L J Aronne et al.   INTERNATIONAL JOURNAL OF OBESITY

A clinical trial assessing the safety and efficacy of the CB1R inverse agonist taranabant in obese and overweight patients: low-dose study

(2010) J Proietto et al.   INTERNATIONAL JOURNAL OF OBESITY

Synthesis and biological evaluation of novel peripherally active morphiceptin analogs

(2010) Katarzyna Gach et al.   PEPTIDES

A one-year study to assess the safety and efficacy of the CB1R inverse agonist taranabant in overweight and obese patients with type 2 diabetes

(2009) M. S. Kipnes et al.   DIABETES OBESITY & METABOLISM

Lubiprostone

(2009) Natalie J. Carter et al.   DRUGS

Activation of the cannabinoid 2 receptor (CB2) protects against experimental colitis

(2009) Martin A. Storr et al.   INFLAMMATORY BOWEL DISEASES

Central and peripheral consequences of the chronic blockade of CB1cannabinoid receptor with rimonabant or taranabant

(2009) Elena Martín-García et al.   JOURNAL OF NEUROCHEMISTRY

Salvinorin A inhibits colonic transit and neurogenic ion transport in mice by activating κ-opioid and cannabinoid receptors

(2009) J. Fichna et al.   NEUROGASTROENTEROLOGY AND MOTILITY

Cannabinoid-1 (CB1) receptors regulate colonic propulsion by acting at motor neurons within the ascending motor pathways in mouse colon

(2008) Andrei Sibaev et al.   AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY

The Acyclic CB1R Inverse Agonist Taranabant Mediates Weight Loss by Increasing Energy Expenditure and Decreasing Caloric Intake

(2008) Carol Addy et al.   Cell Metabolism

The role of the endocannabinoid system in the pathophysiology and treatment of irritable bowel syndrome

(2008) m. a. storr et al.   NEUROGASTROENTEROLOGY AND MOTILITY

Irritable Bowel Syndrome

(2008) Emeran A. Mayer   NEW ENGLAND JOURNAL OF MEDICINE